Novo Nordisk Foundation Injects upto $21m Into Africa Health Research

One of the world's wealthiest philanthropic funders has put money into a research partnership between Africa and Europe, and the timing says as much as the amount.

Global Health EDCTP3 and the Novo Nordisk Foundation announced on 15 June 2026 that the Foundation will contribute up to $21 million to the partnership.

Global Health EDCTP3 is the Africa-Europe research funder backed by the European Union and more than 40 member countries, and it pays for clinical trials and research capacity across sub-Saharan Africa.

The Novo Nordisk Foundation is a Danish philanthropic foundation established in 1924, which funds research into infectious diseases and long-term conditions such as diabetes and heart disease.

The commitment was announced in euros, at up to 18 million, and the dollar figures in this article are conversions at current exchange rates. The words "up to" matter as much as the number. It is a ceiling on the commitment, not a cheque already banked.

Chest infections are first in the queue

The money will support research priorities under the partnership's work programmes for 2026 and 2027.

The clearest destination is a 2026 funding call for new ways to prevent and treat lower respiratory tract infections in sub-Saharan Africa.

These are infections of the airways and lungs, pneumonia being the most familiar, and they remain one of the leading causes of death on the continent, particularly among young children and older adults.

That call has already moved. Global Health EDCTP3 reported that 44 research teams applied by the first-stage deadline of 4 March 2026, competing for a budget of about $39 million.

The shortlisted teams have until 17 September 2026 to submit full proposals. Across all four of the 2026 research topics, the partnership received 277 applications.

When two illnesses meet in the same patient

A second share of the Foundation's contribution is aimed at something less visible: how infectious diseases interact with non-communicable diseases, the long-term conditions such as diabetes, heart disease and chronic lung disease that are not passed from person to person.

Global Health EDCTP3 says the partnership reflects a growing recognition that health problems in Africa are getting more complicated.

Infections remain a heavy burden, while non-communicable diseases are climbing quickly, and health systems built for one are now handling both at once.

Michael Makanga, Executive Director of Global Health EDCTP3, said combining resources allows the partnership to fund "critical research and development" against Africa's dual burden of infectious and non-communicable diseases, while keeping governance in the hands of European and African public bodies.

That last point is the part worth reading twice.

It is the argument the partnership is making for why philanthropic money can come in without private priorities taking over the agenda.

A $21 million cheque against a $2 billion programme

Scale is where reporting on funding announcements usually goes wrong.

Global Health EDCTP3 is running a budget of roughly $2.1 billion, and its 2026 work programme alone put up to about $170 million on the table. Against those figures, up to $21 million from a single philanthropic funder is a contribution rather than a transformation.

What gives it weight is the direction of travel.

Announcing the 2026 programme in January, Makanga noted that global funding was under increasing pressure.

The June announcement is blunter still, describing a global health architecture undergoing profound and lasting change, and saying that sustained commitment from strategic partners and member states will be essential to protect what has already been achieved.

Philanthropy arriving as public donor budgets tighten is one of the defining stories in global health right now. This deal is a small, concrete instance of it.

Two decades of groundwork sit behind this

The partnership is not new money landing on empty ground.

The European and Developing Countries Clinical Trials Partnership, known as EDCTP, has been funding clinical research in sub-Saharan Africa since 2003.

Global Health EDCTP3 is its third phase, operating as an autonomous European Union body, and it has funded 107 research projects since 2022.

By its own account, research supported across the EDCTP programmes has produced nine innovations already in use, from the first malaria vaccines to child-friendly formulations of medicines for HIV, tuberculosis and neglected tropical diseases.

More than 3,000 African scientists and health professionals have been supported through those programmes, many now leading institutions on the continent.

The 2026 funding calls also require strong representation from institutions and researchers in sub-Saharan Africa, which is the mechanism intended to keep the work anchored where the diseases are.

What has been agreed, and what has not

The deal also covers gold sponsorship of the EDCTP Forum 2027, the partnership's main gathering, which runs in Madrid, Spain, from 5 to 9 April 2027.

Both organisations describe the agreement as a first step. Discussions are already underway about expanding cooperation under a possible successor programme to Global Health EDCTP3, though nothing beyond the current commitment has been agreed.

Mads Krogsgaard Thomsen, Chief Executive Officer of the Novo Nordisk Foundation, framed the partnership as an attractive route for philanthropic organisations to increase their impact through African and European collaboration, at a time of complex disease patterns and mounting pressure on health systems.

Henrik Ullum, Chief Executive Officer of Denmark's Statens Serum Institut, welcomed it as an example of philanthropic funders, governments and research institutions working together to strengthen research capacity.

For patients in the countries where this research will run, nothing changes tomorrow. Clinical research moves on a timescale of years, and the projects competing for this money are still being assessed.

The value of an announcement like this is not immediate treatment, but the continuation of a research pipeline that has taken more than twenty years to build and would be far harder to rebuild than to maintain.